This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the
safety and feasibility of super-selective intra-arterial administration of verapamil and
magnesium sulfate immediately following successful endovascular thrombectomy as a potential
neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke.
This trial represents the first time that magnesium sulfate will be evaluated in human
subjects as a superselectively administered neuroprotective agent administered in an acute
time frame as an adjunct to intra-arterial thrombectomy. Furthermore, it will represent the
first trial to evaluate combinational therapy for acute stroke neuroprotection.